News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document - PubMed (original) (raw)
Review
. 2019 Oct;71(4):811-822.
doi: 10.1016/j.jhep.2019.07.002. Epub 2019 Jul 11.
Affiliations
- PMID: 31302175
- DOI: 10.1016/j.jhep.2019.07.002
Review
News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document
Paolo Angeli et al. J Hepatol. 2019 Oct.
Abstract
Renal dysfunction is a common, life-threatening complication occurring in patients with liver disease. Hepatorenal syndrome (HRS) has been defined as a purely "functional" type of renal failure that often occurs in patients with cirrhosis in the setting of marked abnormalities in arterial circulation, as well as overactivity of the endogenous vasoactive systems.4,5 In 2007, the International Club of Ascites (ICA) classified HRS into types 1 and 2 (HRS-1 and HRS-2).5 HRS-1 is characterised by a rapid deterioration of renal function that often occurs because of a precipitating event, while HRS-2 is a moderate and stable or slowly progressive renal dysfunction that often occurs without an obvious precipitant. Clinically, HRS-1 is characterised by acute renal failure while HRS-2 is mainly characterised by refractory ascites. Nevertheless, after these two entities were first described, new concepts, definitions, and diagnostic criteria have been developed by nephrologists for renal dysfunction in the general population and hospitalised patients. In particular, the definitions and characterisation of acute kidney injury (AKI), acute kidney disease and chronic kidney disease have been introduced/refined.6 Accordingly, a debate among hepatologists of the ICA led to a complete revision of the nomenclature and diagnosistic criteria for HRS-1, which was renamed HRS-AKI.7 Additionally, over recent years, greater granularity has been gained regarding the pathogenesis of HRS; it is now increasingly recognised that it is not a purely "functional" entity with haemodynamic derangements, but that systemic inflammation, oxidative stress and bile salt-related tubular damage may contribute significantly to its development. That is, HRS has an additional structural component that would not only make traditional diagnostic criteria less reliable, but would explain the lack of response to pharmacological treatment with vasoconstrictors plus albumin that correlates with a progressive increase in inflammation. Because classification, nomenclature, diagnostic criteria and pathogenic theories have evolved over the years since the traditional classification of HRS-1 and HRS-2 was first described, it was considered that all these novel aspects be reviewed and summarised in a position paper. The aim of this position paper authored by two hepatologists (members of ICA) and two nephrologists involved in the study of renal dysfunction in cirrhosis, is to complete the re-classification of HRS initiated by the ICA in 2012 and to provide an update on the definition, classification, diagnosis, pathophysiology and treatment of HRS.
Keywords: Acute Kidney Disease; Acute Liver Failure; Acute kidney Injury; Acute on chronic liver failure; Albumin; Biomarkers; Chronic Kidney Disease; Cirrhosis; Liver Disease; Liver transplantation; MELD; Midodrine; NGAL; Noradrenaline; Portal Hypertension; Serum creatinine; Simultaneous liver Kidney Transplantation; Systemic Inflammation; Terlipressin.
Copyright © 2019. Published by Elsevier B.V.
Comment in
- Reply to: "Lack of evidence for a continuum between hepatorenal syndrome and acute tubular necrosis".
Garcia-Tsao G, Angeli P, Nadim MK, Parikh CR. Garcia-Tsao G, et al. J Hepatol. 2020 Mar;72(3):582-583. doi: 10.1016/j.jhep.2019.11.005. Epub 2019 Dec 4. J Hepatol. 2020. PMID: 31810532 No abstract available. - Lack of evidence for a continuum between hepatorenal syndrome and acute tubular necrosis.
Solé C, Solà E, Kamath PS, Ginès P. Solé C, et al. J Hepatol. 2020 Mar;72(3):581-582. doi: 10.1016/j.jhep.2019.09.016. Epub 2019 Dec 10. J Hepatol. 2020. PMID: 31836264 No abstract available.
Similar articles
- AGA Clinical Practice Update on the Evaluation and Management of Acute Kidney Injury in Patients With Cirrhosis: Expert Review.
Flamm SL, Wong F, Ahn J, Kamath PS. Flamm SL, et al. Clin Gastroenterol Hepatol. 2022 Dec;20(12):2707-2716. doi: 10.1016/j.cgh.2022.08.033. Epub 2022 Sep 6. Clin Gastroenterol Hepatol. 2022. PMID: 36075500 Review. - New Developments in Hepatorenal Syndrome.
Mindikoglu AL, Pappas SC. Mindikoglu AL, et al. Clin Gastroenterol Hepatol. 2018 Feb;16(2):162-177.e1. doi: 10.1016/j.cgh.2017.05.041. Epub 2017 Jun 7. Clin Gastroenterol Hepatol. 2018. PMID: 28602971 Free PMC article. Review. - Hepatorenal Syndrome Type 1: Current Challenges And Future Prospects.
Facciorusso A. Facciorusso A. Ther Clin Risk Manag. 2019 Nov 27;15:1383-1391. doi: 10.2147/TCRM.S205328. eCollection 2019. Ther Clin Risk Manag. 2019. PMID: 31819465 Free PMC article. Review. - Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting.
Nadim MK, Kellum JA, Forni L, Francoz C, Asrani SK, Ostermann M, Allegretti AS, Neyra JA, Olson JC, Piano S, VanWagner LB, Verna EC, Akcan-Arikan A, Angeli P, Belcher JM, Biggins SW, Deep A, Garcia-Tsao G, Genyk YS, Gines P, Kamath PS, Kane-Gill SL, Kaushik M, Lumlertgul N, Macedo E, Maiwall R, Marciano S, Pichler RH, Ronco C, Tandon P, Velez JQ, Mehta RL, Durand F. Nadim MK, et al. J Hepatol. 2024 Jul;81(1):163-183. doi: 10.1016/j.jhep.2024.03.031. Epub 2024 Mar 26. J Hepatol. 2024. PMID: 38527522 Free PMC article. Review. - An Integrated Review of the Hepatorenal Syndrome.
Ojeda-Yuren AS, Cerda-Reyes E, Herrero-Maceda MR, Castro-Narro G, Piano S. Ojeda-Yuren AS, et al. Ann Hepatol. 2021 May-Jun;22:100236. doi: 10.1016/j.aohep.2020.07.008. Epub 2020 Aug 23. Ann Hepatol. 2021. PMID: 32846202 Review.
Cited by
- Recent insights into contributing factors in the pathogenesis of cirrhotic ascites.
Li Z, Zhu J, Ouyang H. Li Z, et al. Front Med (Lausanne). 2024 Sep 13;11:1376217. doi: 10.3389/fmed.2024.1376217. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39346937 Free PMC article. Review. - Efficacy of albumin use in decompensated cirrhosis and real-world adoption in Australia.
Kalo E, Read S, Baig A, Marshall K, Ma WS, Crowther H, Gofton C, Lynch KD, Sood S, Holmes J, Lubel J, Wigg A, McCaughan G, Roberts SK, Caraceni P, Ahlenstiel G, Majumdar A. Kalo E, et al. JGH Open. 2024 Sep 18;8(9):e70029. doi: 10.1002/jgh3.70029. eCollection 2024 Sep. JGH Open. 2024. PMID: 39301299 Free PMC article. Review. - Effects of Transjugular Intrahepatic Portosystemic Shunt on Renal and Pulmonary Function in Hepatic Decompensation with and without Hepatorenal and Hepatopulmonary Syndromes: A Review.
Abdelwahed AH, Aboeldahb M, Wu GY. Abdelwahed AH, et al. J Clin Transl Hepatol. 2024 Sep 28;12(9):780-791. doi: 10.14218/JCTH.2024.00188. Epub 2024 Jul 25. J Clin Transl Hepatol. 2024. PMID: 39280072 Free PMC article. Review. - Efficacy and Safety of Terlipressin Infusion in Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI): A Retrospective Observational Study.
Gowda M, Dilipbhai DM, Jalihal U, Kumar MP, Gowda S B, Jain A, Ganjoo N. Gowda M, et al. Cureus. 2024 Aug 10;16(8):e66581. doi: 10.7759/cureus.66581. eCollection 2024 Aug. Cureus. 2024. PMID: 39252705 Free PMC article. - T1 mapping combined with arterial spin labeling MRI to identify renal injury in patients with liver cirrhosis.
Xie S, Chen M, Chen C, Zhao Y, Qin J, Qiu C, Zhu J, Nickel MD, Kuehn B, Shen W. Xie S, et al. Front Endocrinol (Lausanne). 2024 Aug 9;15:1363797. doi: 10.3389/fendo.2024.1363797. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39184137 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous